aluates Reports

$ 0.0

Automative

Global Non-melanoma Skin Cancer Drugs Market Research Report 2024

Published Date: June 2024

Report Code: QYRE-Auto-16W12223

Global Non melanoma Skin Cancer Drugs Market Research Report 2022

BUY CHAPTERS

Global Non-melanoma Skin Cancer Drugs Market Research Report 2024

Code: QYRE-Auto-16W12223

Report

June 2024

Pages:107

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bausch Health

Mayne Pharma

Roche

United Laboratories

Perrigo

Biological E.

Glenmark Pharmaceuticals

Sichuan Med-Shine Pharmaceutical

Henan Topfond Pharmaceutical

Bristol–Myers Squibb

Sun Pharma

Qilu Pharmaceutical

Hansoh Pharma

Celgene Corporation

Taj Accura

Khandelwal Laboratories Pvt.Ltd

Luye Pharma

Beijing Youcare

Beijing Union Pharmaceutical Factory

Hainan Haiyao

Chuntch

Regeneron (Sanofi)

Non-melanoma Skin Cancer Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Non-melanoma Skin Cancer Drugs Market

The global Non-melanoma Skin Cancer Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Non-melanoma Skin Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-melanoma Skin Cancer Drugs.

Report Scope

The Non-melanoma Skin Cancer Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-melanoma Skin Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-melanoma Skin Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Non-melanoma Skin Cancer Drugs Market Report

Report Metric	Details
Report Name	Non-melanoma Skin Cancer Drugs Market
CAGR	5%
Segment by Type	Imiquimod Cream 5-fluorouracil Cream Vismodegib Cemiplimab Cisplatin Paclitaxel
Segment by Application	Basal Cell Carcinoma (BCC) Squamous Cell Carcinoma (SCC)
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Bausch Health, Mayne Pharma, Roche, United Laboratories, 3M, Perrigo, Biological E., Glenmark Pharmaceuticals, Sichuan Med-shine Pharmaceutical, Henan Topfond Pharmaceutical, Regeneron (Sanofi), Bristol-Myers Squibb, Sun Pharma, Qilu Pharmaceutical, Hansoh Pharma, Celgene Corporation, Taj Accura, Khandelwal Laboratories Pvt Ltd., Luye Pharma, Beijing Youcare, Beijing Union Pharmaceutical Factory, Hainan Haiyao, Chuntch
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-melanoma Skin Cancer Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Non-melanoma Skin Cancer Drugs Market report?

Ans: The main players in the Non-melanoma Skin Cancer Drugs Market are Pfizer, Bausch Health, Mayne Pharma, Roche, United Laboratories, 3M, Perrigo, Biological E., Glenmark Pharmaceuticals, Sichuan Med-shine Pharmaceutical, Henan Topfond Pharmaceutical, Regeneron (Sanofi), Bristol-Myers Squibb, Sun Pharma, Qilu Pharmaceutical, Hansoh Pharma, Celgene Corporation, Taj Accura, Khandelwal Laboratories Pvt Ltd., Luye Pharma, Beijing Youcare, Beijing Union Pharmaceutical Factory, Hainan Haiyao, Chuntch

What are the Application segmentation covered in the Non-melanoma Skin Cancer Drugs Market report?

Ans: The Applications covered in the Non-melanoma Skin Cancer Drugs Market report are Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC)

What are the Type segmentation covered in the Non-melanoma Skin Cancer Drugs Market report?

Ans: The Types covered in the Non-melanoma Skin Cancer Drugs Market report are Imiquimod Cream, 5-fluorouracil Cream, Vismodegib, Cemiplimab, Cisplatin, Paclitaxel

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non-melanoma Skin Cancer Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Imiquimod Cream

1.2.3 5-fluorouracil Cream

1.2.4 Vismodegib

1.2.5 Cemiplimab

1.2.6 Cisplatin

1.2.7 Paclitaxel

1.3 Market by Application

1.3.1 Global Non-melanoma Skin Cancer Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Basal Cell Carcinoma (BCC)

1.3.3 Squamous Cell Carcinoma (SCC)

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Non-melanoma Skin Cancer Drugs Market Perspective (2019-2030)

2.2 Non-melanoma Skin Cancer Drugs Growth Trends by Region

2.2.1 Global Non-melanoma Skin Cancer Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Non-melanoma Skin Cancer Drugs Historic Market Size by Region (2019-2024)

2.2.3 Non-melanoma Skin Cancer Drugs Forecasted Market Size by Region (2025-2030)

2.3 Non-melanoma Skin Cancer Drugs Market Dynamics

2.3.1 Non-melanoma Skin Cancer Drugs Industry Trends

2.3.2 Non-melanoma Skin Cancer Drugs Market Drivers

2.3.3 Non-melanoma Skin Cancer Drugs Market Challenges

2.3.4 Non-melanoma Skin Cancer Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Non-melanoma Skin Cancer Drugs Players by Revenue

3.1.1 Global Top Non-melanoma Skin Cancer Drugs Players by Revenue (2019-2024)

3.1.2 Global Non-melanoma Skin Cancer Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Non-melanoma Skin Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Non-melanoma Skin Cancer Drugs Revenue

3.4 Global Non-melanoma Skin Cancer Drugs Market Concentration Ratio

3.4.1 Global Non-melanoma Skin Cancer Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non-melanoma Skin Cancer Drugs Revenue in 2023

3.5 Non-melanoma Skin Cancer Drugs Key Players Head office and Area Served

3.6 Key Players Non-melanoma Skin Cancer Drugs Product Solution and Service

3.7 Date of Enter into Non-melanoma Skin Cancer Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Non-melanoma Skin Cancer Drugs Breakdown Data by Type

4.1 Global Non-melanoma Skin Cancer Drugs Historic Market Size by Type (2019-2024)

4.2 Global Non-melanoma Skin Cancer Drugs Forecasted Market Size by Type (2025-2030)

5 Non-melanoma Skin Cancer Drugs Breakdown Data by Application

5.1 Global Non-melanoma Skin Cancer Drugs Historic Market Size by Application (2019-2024)

5.2 Global Non-melanoma Skin Cancer Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Non-melanoma Skin Cancer Drugs Market Size (2019-2030)

6.2 North America Non-melanoma Skin Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Non-melanoma Skin Cancer Drugs Market Size by Country (2019-2024)

6.4 North America Non-melanoma Skin Cancer Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Non-melanoma Skin Cancer Drugs Market Size (2019-2030)

7.2 Europe Non-melanoma Skin Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Non-melanoma Skin Cancer Drugs Market Size by Country (2019-2024)

7.4 Europe Non-melanoma Skin Cancer Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Non-melanoma Skin Cancer Drugs Market Size (2019-2030)

8.2 Asia-Pacific Non-melanoma Skin Cancer Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Non-melanoma Skin Cancer Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Non-melanoma Skin Cancer Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Non-melanoma Skin Cancer Drugs Market Size (2019-2030)

9.2 Latin America Non-melanoma Skin Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Non-melanoma Skin Cancer Drugs Market Size by Country (2019-2024)

9.4 Latin America Non-melanoma Skin Cancer Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Non-melanoma Skin Cancer Drugs Market Size (2019-2030)

10.2 Middle East & Africa Non-melanoma Skin Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Non-melanoma Skin Cancer Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Non-melanoma Skin Cancer Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Detail

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Non-melanoma Skin Cancer Drugs Introduction

11.1.4 Pfizer Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.1.5 Pfizer Recent Development

11.2 Bausch Health

11.2.1 Bausch Health Company Detail

11.2.2 Bausch Health Business Overview

11.2.3 Bausch Health Non-melanoma Skin Cancer Drugs Introduction

11.2.4 Bausch Health Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.2.5 Bausch Health Recent Development

11.3 Mayne Pharma

11.3.1 Mayne Pharma Company Detail

11.3.2 Mayne Pharma Business Overview

11.3.3 Mayne Pharma Non-melanoma Skin Cancer Drugs Introduction

11.3.4 Mayne Pharma Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.3.5 Mayne Pharma Recent Development

11.4 Roche

11.4.1 Roche Company Detail

11.4.2 Roche Business Overview

11.4.3 Roche Non-melanoma Skin Cancer Drugs Introduction

11.4.4 Roche Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.4.5 Roche Recent Development

11.5 United Laboratories

11.5.1 United Laboratories Company Detail

11.5.2 United Laboratories Business Overview

11.5.3 United Laboratories Non-melanoma Skin Cancer Drugs Introduction

11.5.4 United Laboratories Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.5.5 United Laboratories Recent Development

11.6 3M

11.6.1 3M Company Detail

11.6.2 3M Business Overview

11.6.3 3M Non-melanoma Skin Cancer Drugs Introduction

11.6.4 3M Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.6.5 3M Recent Development

11.7 Perrigo

11.7.1 Perrigo Company Detail

11.7.2 Perrigo Business Overview

11.7.3 Perrigo Non-melanoma Skin Cancer Drugs Introduction

11.7.4 Perrigo Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.7.5 Perrigo Recent Development

11.8 Biological E.

11.8.1 Biological E. Company Detail

11.8.2 Biological E. Business Overview

11.8.3 Biological E. Non-melanoma Skin Cancer Drugs Introduction

11.8.4 Biological E. Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.8.5 Biological E. Recent Development

11.9 Glenmark Pharmaceuticals

11.9.1 Glenmark Pharmaceuticals Company Detail

11.9.2 Glenmark Pharmaceuticals Business Overview

11.9.3 Glenmark Pharmaceuticals Non-melanoma Skin Cancer Drugs Introduction

11.9.4 Glenmark Pharmaceuticals Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.9.5 Glenmark Pharmaceuticals Recent Development

11.10 Sichuan Med-shine Pharmaceutical

11.10.1 Sichuan Med-shine Pharmaceutical Company Detail

11.10.2 Sichuan Med-shine Pharmaceutical Business Overview

11.10.3 Sichuan Med-shine Pharmaceutical Non-melanoma Skin Cancer Drugs Introduction

11.10.4 Sichuan Med-shine Pharmaceutical Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.10.5 Sichuan Med-shine Pharmaceutical Recent Development

11.11 Henan Topfond Pharmaceutical

11.11.1 Henan Topfond Pharmaceutical Company Detail

11.11.2 Henan Topfond Pharmaceutical Business Overview

11.11.3 Henan Topfond Pharmaceutical Non-melanoma Skin Cancer Drugs Introduction

11.11.4 Henan Topfond Pharmaceutical Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.11.5 Henan Topfond Pharmaceutical Recent Development

11.12 Regeneron (Sanofi)

11.12.1 Regeneron (Sanofi) Company Detail

11.12.2 Regeneron (Sanofi) Business Overview

11.12.3 Regeneron (Sanofi) Non-melanoma Skin Cancer Drugs Introduction

11.12.4 Regeneron (Sanofi) Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.12.5 Regeneron (Sanofi) Recent Development

11.13 Bristol-Myers Squibb

11.13.1 Bristol-Myers Squibb Company Detail

11.13.2 Bristol-Myers Squibb Business Overview

11.13.3 Bristol-Myers Squibb Non-melanoma Skin Cancer Drugs Introduction

11.13.4 Bristol-Myers Squibb Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.13.5 Bristol-Myers Squibb Recent Development

11.14 Sun Pharma

11.14.1 Sun Pharma Company Detail

11.14.2 Sun Pharma Business Overview

11.14.3 Sun Pharma Non-melanoma Skin Cancer Drugs Introduction

11.14.4 Sun Pharma Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.14.5 Sun Pharma Recent Development

11.15 Qilu Pharmaceutical

11.15.1 Qilu Pharmaceutical Company Detail

11.15.2 Qilu Pharmaceutical Business Overview

11.15.3 Qilu Pharmaceutical Non-melanoma Skin Cancer Drugs Introduction

11.15.4 Qilu Pharmaceutical Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.15.5 Qilu Pharmaceutical Recent Development

11.16 Hansoh Pharma

11.16.1 Hansoh Pharma Company Detail

11.16.2 Hansoh Pharma Business Overview

11.16.3 Hansoh Pharma Non-melanoma Skin Cancer Drugs Introduction

11.16.4 Hansoh Pharma Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.16.5 Hansoh Pharma Recent Development

11.17 Celgene Corporation

11.17.1 Celgene Corporation Company Detail

11.17.2 Celgene Corporation Business Overview

11.17.3 Celgene Corporation Non-melanoma Skin Cancer Drugs Introduction

11.17.4 Celgene Corporation Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.17.5 Celgene Corporation Recent Development

11.18 Taj Accura

11.18.1 Taj Accura Company Detail

11.18.2 Taj Accura Business Overview

11.18.3 Taj Accura Non-melanoma Skin Cancer Drugs Introduction

11.18.4 Taj Accura Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.18.5 Taj Accura Recent Development

11.19 Khandelwal Laboratories Pvt Ltd.

11.19.1 Khandelwal Laboratories Pvt Ltd. Company Detail

11.19.2 Khandelwal Laboratories Pvt Ltd. Business Overview

11.19.3 Khandelwal Laboratories Pvt Ltd. Non-melanoma Skin Cancer Drugs Introduction

11.19.4 Khandelwal Laboratories Pvt Ltd. Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.19.5 Khandelwal Laboratories Pvt Ltd. Recent Development

11.20 Luye Pharma

11.20.1 Luye Pharma Company Detail

11.20.2 Luye Pharma Business Overview

11.20.3 Luye Pharma Non-melanoma Skin Cancer Drugs Introduction

11.20.4 Luye Pharma Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.20.5 Luye Pharma Recent Development

11.21 Beijing Youcare

11.21.1 Beijing Youcare Company Detail

11.21.2 Beijing Youcare Business Overview

11.21.3 Beijing Youcare Non-melanoma Skin Cancer Drugs Introduction

11.21.4 Beijing Youcare Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.21.5 Beijing Youcare Recent Development

11.22 Beijing Union Pharmaceutical Factory

11.22.1 Beijing Union Pharmaceutical Factory Company Detail

11.22.2 Beijing Union Pharmaceutical Factory Business Overview

11.22.3 Beijing Union Pharmaceutical Factory Non-melanoma Skin Cancer Drugs Introduction

11.22.4 Beijing Union Pharmaceutical Factory Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.22.5 Beijing Union Pharmaceutical Factory Recent Development

11.23 Hainan Haiyao

11.23.1 Hainan Haiyao Company Detail

11.23.2 Hainan Haiyao Business Overview

11.23.3 Hainan Haiyao Non-melanoma Skin Cancer Drugs Introduction

11.23.4 Hainan Haiyao Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.23.5 Hainan Haiyao Recent Development

11.24 Chuntch

11.24.1 Chuntch Company Detail

11.24.2 Chuntch Business Overview

11.24.3 Chuntch Non-melanoma Skin Cancer Drugs Introduction

11.24.4 Chuntch Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024)

11.24.5 Chuntch Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Bausch Health

Mayne Pharma

Roche

United Laboratories

Perrigo

Biological E.

Glenmark Pharmaceuticals

Sichuan Med-Shine Pharmaceutical

Henan Topfond Pharmaceutical

Bristol–Myers Squibb

Sun Pharma

Qilu Pharmaceutical

Hansoh Pharma

Celgene Corporation

Taj Accura

Khandelwal Laboratories Pvt.Ltd

Luye Pharma

Beijing Youcare

Beijing Union Pharmaceutical Factory

Hainan Haiyao

Chuntch

Regeneron (Sanofi)

List of Tables

Table 1. Global Non-melanoma Skin Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Imiquimod Cream

Table 3. Key Players of 5-fluorouracil Cream

Table 4. Key Players of Vismodegib

Table 5. Key Players of Cemiplimab

Table 6. Key Players of Cisplatin

Table 7. Key Players of Paclitaxel

Table 8. Global Non-melanoma Skin Cancer Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Non-melanoma Skin Cancer Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 10. Global Non-melanoma Skin Cancer Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 11. Global Non-melanoma Skin Cancer Drugs Market Share by Region (2019-2024)

Table 12. Global Non-melanoma Skin Cancer Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 13. Global Non-melanoma Skin Cancer Drugs Market Share by Region (2025-2030)

Table 14. Non-melanoma Skin Cancer Drugs Market Trends

Table 15. Non-melanoma Skin Cancer Drugs Market Drivers

Table 16. Non-melanoma Skin Cancer Drugs Market Challenges

Table 17. Non-melanoma Skin Cancer Drugs Market Restraints

Table 18. Global Non-melanoma Skin Cancer Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 19. Global Non-melanoma Skin Cancer Drugs Market Share by Players (2019-2024)

Table 20. Global Top Non-melanoma Skin Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-melanoma Skin Cancer Drugs as of 2023)

Table 21. Ranking of Global Top Non-melanoma Skin Cancer Drugs Companies by Revenue (US$ Million) in 2023

Table 22. Global 5 Largest Players Market Share by Non-melanoma Skin Cancer Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 23. Key Players Headquarters and Area Served

Table 24. Key Players Non-melanoma Skin Cancer Drugs Product Solution and Service

Table 25. Date of Enter into Non-melanoma Skin Cancer Drugs Market

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Non-melanoma Skin Cancer Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 28. Global Non-melanoma Skin Cancer Drugs Revenue Market Share by Type (2019-2024)

Table 29. Global Non-melanoma Skin Cancer Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 30. Global Non-melanoma Skin Cancer Drugs Revenue Market Share by Type (2025-2030)

Table 31. Global Non-melanoma Skin Cancer Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 32. Global Non-melanoma Skin Cancer Drugs Revenue Market Share by Application (2019-2024)

Table 33. Global Non-melanoma Skin Cancer Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 34. Global Non-melanoma Skin Cancer Drugs Revenue Market Share by Application (2025-2030)

Table 35. North America Non-melanoma Skin Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. North America Non-melanoma Skin Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 37. North America Non-melanoma Skin Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 38. Europe Non-melanoma Skin Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. Europe Non-melanoma Skin Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 40. Europe Non-melanoma Skin Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 41. Asia-Pacific Non-melanoma Skin Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 42. Asia-Pacific Non-melanoma Skin Cancer Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 43. Asia-Pacific Non-melanoma Skin Cancer Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 44. Latin America Non-melanoma Skin Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Latin America Non-melanoma Skin Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 46. Latin America Non-melanoma Skin Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 47. Middle East & Africa Non-melanoma Skin Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 48. Middle East & Africa Non-melanoma Skin Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Non-melanoma Skin Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 50. Pfizer Company Detail

Table 51. Pfizer Business Overview

Table 52. Pfizer Non-melanoma Skin Cancer Drugs Product

Table 53. Pfizer Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 54. Pfizer Recent Development

Table 55. Bausch Health Company Detail

Table 56. Bausch Health Business Overview

Table 57. Bausch Health Non-melanoma Skin Cancer Drugs Product

Table 58. Bausch Health Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 59. Bausch Health Recent Development

Table 60. Mayne Pharma Company Detail

Table 61. Mayne Pharma Business Overview

Table 62. Mayne Pharma Non-melanoma Skin Cancer Drugs Product

Table 63. Mayne Pharma Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 64. Mayne Pharma Recent Development

Table 65. Roche Company Detail

Table 66. Roche Business Overview

Table 67. Roche Non-melanoma Skin Cancer Drugs Product

Table 68. Roche Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 69. Roche Recent Development

Table 70. United Laboratories Company Detail

Table 71. United Laboratories Business Overview

Table 72. United Laboratories Non-melanoma Skin Cancer Drugs Product

Table 73. United Laboratories Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 74. United Laboratories Recent Development

Table 75. 3M Company Detail

Table 76. 3M Business Overview

Table 77. 3M Non-melanoma Skin Cancer Drugs Product

Table 78. 3M Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 79. 3M Recent Development

Table 80. Perrigo Company Detail

Table 81. Perrigo Business Overview

Table 82. Perrigo Non-melanoma Skin Cancer Drugs Product

Table 83. Perrigo Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 84. Perrigo Recent Development

Table 85. Biological E. Company Detail

Table 86. Biological E. Business Overview

Table 87. Biological E. Non-melanoma Skin Cancer Drugs Product

Table 88. Biological E. Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 89. Biological E. Recent Development

Table 90. Glenmark Pharmaceuticals Company Detail

Table 91. Glenmark Pharmaceuticals Business Overview

Table 92. Glenmark Pharmaceuticals Non-melanoma Skin Cancer Drugs Product

Table 93. Glenmark Pharmaceuticals Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 94. Glenmark Pharmaceuticals Recent Development

Table 95. Sichuan Med-shine Pharmaceutical Company Detail

Table 96. Sichuan Med-shine Pharmaceutical Business Overview

Table 97. Sichuan Med-shine Pharmaceutical Non-melanoma Skin Cancer Drugs Product

Table 98. Sichuan Med-shine Pharmaceutical Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 99. Sichuan Med-shine Pharmaceutical Recent Development

Table 100. Henan Topfond Pharmaceutical Company Detail

Table 101. Henan Topfond Pharmaceutical Business Overview

Table 102. Henan Topfond Pharmaceutical Non-melanoma Skin Cancer Drugs Product

Table 103. Henan Topfond Pharmaceutical Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 104. Henan Topfond Pharmaceutical Recent Development

Table 105. Regeneron (Sanofi) Company Detail

Table 106. Regeneron (Sanofi) Business Overview

Table 107. Regeneron (Sanofi) Non-melanoma Skin Cancer Drugs Product

Table 108. Regeneron (Sanofi) Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 109. Regeneron (Sanofi) Recent Development

Table 110. Bristol-Myers Squibb Company Detail

Table 111. Bristol-Myers Squibb Business Overview

Table 112. Bristol-Myers Squibb Non-melanoma Skin Cancer Drugs Product

Table 113. Bristol-Myers Squibb Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 114. Bristol-Myers Squibb Recent Development

Table 115. Sun Pharma Company Detail

Table 116. Sun Pharma Business Overview

Table 117. Sun Pharma Non-melanoma Skin Cancer Drugs Product

Table 118. Sun Pharma Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 119. Sun Pharma Recent Development

Table 120. Qilu Pharmaceutical Company Detail

Table 121. Qilu Pharmaceutical Business Overview

Table 122. Qilu Pharmaceutical Non-melanoma Skin Cancer Drugs Product

Table 123. Qilu Pharmaceutical Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 124. Qilu Pharmaceutical Recent Development

Table 125. Hansoh Pharma Company Detail

Table 126. Hansoh Pharma Business Overview

Table 127. Hansoh Pharma Non-melanoma Skin Cancer Drugs Product

Table 128. Hansoh Pharma Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 129. Hansoh Pharma Recent Development

Table 130. Celgene Corporation Company Detail

Table 131. Celgene Corporation Business Overview

Table 132. Celgene Corporation Non-melanoma Skin Cancer Drugs Product

Table 133. Celgene Corporation Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 134. Celgene Corporation Recent Development

Table 135. Taj Accura Company Detail

Table 136. Taj Accura Business Overview

Table 137. Taj Accura Non-melanoma Skin Cancer Drugs Product

Table 138. Taj Accura Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 139. Taj Accura Recent Development

Table 140. Khandelwal Laboratories Pvt Ltd. Company Detail

Table 141. Khandelwal Laboratories Pvt Ltd. Business Overview

Table 142. Khandelwal Laboratories Pvt Ltd. Non-melanoma Skin Cancer Drugs Product

Table 143. Khandelwal Laboratories Pvt Ltd. Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 144. Khandelwal Laboratories Pvt Ltd. Recent Development

Table 145. Luye Pharma Company Detail

Table 146. Luye Pharma Business Overview

Table 147. Luye Pharma Non-melanoma Skin Cancer Drugs Product

Table 148. Luye Pharma Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 149. Luye Pharma Recent Development

Table 150. Beijing Youcare Company Detail

Table 151. Beijing Youcare Business Overview

Table 152. Beijing Youcare Non-melanoma Skin Cancer Drugs Product

Table 153. Beijing Youcare Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 154. Beijing Youcare Recent Development

Table 155. Beijing Union Pharmaceutical Factory Company Detail

Table 156. Beijing Union Pharmaceutical Factory Business Overview

Table 157. Beijing Union Pharmaceutical Factory Non-melanoma Skin Cancer Drugs Product

Table 158. Beijing Union Pharmaceutical Factory Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 159. Beijing Union Pharmaceutical Factory Recent Development

Table 160. Hainan Haiyao Company Detail

Table 161. Hainan Haiyao Business Overview

Table 162. Hainan Haiyao Non-melanoma Skin Cancer Drugs Product

Table 163. Hainan Haiyao Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 164. Hainan Haiyao Recent Development

Table 165. Chuntch Company Detail

Table 166. Chuntch Business Overview

Table 167. Chuntch Non-melanoma Skin Cancer Drugs Product

Table 168. Chuntch Revenue in Non-melanoma Skin Cancer Drugs Business (2019-2024) & (US$ Million)

Table 169. Chuntch Recent Development

Table 170. Research Programs/Design for This Report

Table 171. Key Data Information from Secondary Sources

Table 172. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Non-melanoma Skin Cancer Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Non-melanoma Skin Cancer Drugs Market Share by Type: 2023 VS 2030

Figure 3. Imiquimod Cream Features

Figure 4. 5-fluorouracil Cream Features

Figure 5. Vismodegib Features

Figure 6. Cemiplimab Features

Figure 7. Cisplatin Features

Figure 8. Paclitaxel Features

Figure 9. Global Non-melanoma Skin Cancer Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 10. Global Non-melanoma Skin Cancer Drugs Market Share by Application: 2023 VS 2030

Figure 11. Basal Cell Carcinoma (BCC) Case Studies

Figure 12. Squamous Cell Carcinoma (SCC) Case Studies

Figure 13. Non-melanoma Skin Cancer Drugs Report Years Considered

Figure 14. Global Non-melanoma Skin Cancer Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global Non-melanoma Skin Cancer Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Non-melanoma Skin Cancer Drugs Market Share by Region: 2023 VS 2030

Figure 17. Global Non-melanoma Skin Cancer Drugs Market Share by Players in 2023

Figure 18. Global Top Non-melanoma Skin Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-melanoma Skin Cancer Drugs as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by Non-melanoma Skin Cancer Drugs Revenue in 2023

Figure 20. North America Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America Non-melanoma Skin Cancer Drugs Market Share by Country (2019-2030)

Figure 22. United States Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Non-melanoma Skin Cancer Drugs Market Share by Country (2019-2030)

Figure 26. Germany Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. France Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. U.K. Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Italy Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Russia Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Nordic Countries Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Non-melanoma Skin Cancer Drugs Market Share by Region (2019-2030)

Figure 34. China Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Japan Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. South Korea Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Southeast Asia Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. India Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Australia Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Non-melanoma Skin Cancer Drugs Market Share by Country (2019-2030)

Figure 42. Mexico Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Brazil Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Non-melanoma Skin Cancer Drugs Market Share by Country (2019-2030)

Figure 46. Turkey Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Saudi Arabia Non-melanoma Skin Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Pfizer Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 49. Bausch Health Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 50. Mayne Pharma Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 51. Roche Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 52. United Laboratories Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 53. 3M Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 54. Perrigo Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 55. Biological E. Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 56. Glenmark Pharmaceuticals Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 57. Sichuan Med-shine Pharmaceutical Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 58. Henan Topfond Pharmaceutical Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 59. Regeneron (Sanofi) Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 61. Sun Pharma Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 62. Qilu Pharmaceutical Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 63. Hansoh Pharma Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 64. Celgene Corporation Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 65. Taj Accura Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 66. Khandelwal Laboratories Pvt Ltd. Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 67. Luye Pharma Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 68. Beijing Youcare Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 69. Beijing Union Pharmaceutical Factory Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 70. Hainan Haiyao Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 71. Chuntch Revenue Growth Rate in Non-melanoma Skin Cancer Drugs Business (2019-2024)

Figure 72. Bottom-up and Top-down Approaches for This Report

Figure 73. Data Triangulation

Figure 74. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions